Epithelioid leiomyosarcoma of uterus

Setia, Aparna; Kanotra, Shalini; Aggarwal, Ritika; Bhavthankar, Dilip Prabhakarrao

doi:10.1136/bcr.11.2011.5144

Cited by 7 publications

(12 citation statements)

References 18 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 91 The documented incidence of transformation from uterine leiomyoma to ULMS, however, is rare (<0.1%). 89 The 5-year survival rate for LMS is 40%, but decreases to 10%–15% for high-grade LMS 92 and 15%–25% for ULMS. 90 , 91 The standard of care for LMS is surgical resection when possible.…”

Section: Leiomyosarcomamentioning

confidence: 99%

“… 86 LMS can remain dormant for extended periods, and the best outcomes occur after early surgical excision with wide margins. 92 , 93 The 5-year rate of relapse is 40%, which is associated with very high mortality. 92 , 93 …”

Section: Leiomyosarcomamentioning

confidence: 99%

“…CD47 is a cell surface marker that is overexpressed by cancer cells (87% of cases) relative to normal muscle tissues; CD47 prevents cells from being phagocytized by macrophages of the immune system. 92 , 117 LMS has also shown high infiltration of tumor-associated macrophages, which can promote cancer-cell aggressiveness, and patients have shown significantly poorer prognoses 92 , 117 Edris et al hypothesized that blocking the antiphagocytosis function of CD47 would allow infiltrated macrophages already present in the LMS tumor to switch from a protumor to antitumor function and eliminate the tumor cells within the tumor. 92 , 117 In vitro cell-based studies demonstrated phagocytosis of LMS cells by macrophages when treated with an anti-CD47 antibody.…”

Section: Leiomyosarcomamentioning

confidence: 99%

“… 92 , 117 LMS has also shown high infiltration of tumor-associated macrophages, which can promote cancer-cell aggressiveness, and patients have shown significantly poorer prognoses 92 , 117 Edris et al hypothesized that blocking the antiphagocytosis function of CD47 would allow infiltrated macrophages already present in the LMS tumor to switch from a protumor to antitumor function and eliminate the tumor cells within the tumor. 92 , 117 In vitro cell-based studies demonstrated phagocytosis of LMS cells by macrophages when treated with an anti-CD47 antibody. 92 Anti-CD47 treatment drastically reduced tumor mass in vivo in the range of 5- to 30-fold, with few to no distal metastases compared to the controls; a nearly 70-fold decrease in distal metastases was also reported.…”

Section: Leiomyosarcomamentioning

confidence: 99%

See 3 more Smart Citations

A review of soft-tissue sarcomas: translation of biological advances into treatment measures

Hoang¹,

Acevedo²,

Mann³

et al. 2018

CMAR

109

176

View full text Add to dashboard Cite

Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an overall incidence of about five per 100,000 per year. While this diverse family of malignancies comprises over 100 histological subtypes and many molecular aberrations are prevalent within specific sarcomas, very few are therapeutically targeted. Instead of utilizing molecular signatures, first-line sarcoma treatment options are still limited to traditional surgery and chemotherapy, and many of the latter remain largely ineffective and are plagued by disease resistance. Currently, the mechanism of sarcoma oncogenesis remains largely unknown, thus necessitating a better understanding of pathogenesis. Although substantial progress has not occurred with molecularly targeted therapies over the past 30 years, increased knowledge about sarcoma biology could lead to new and more effective treatment strategies to move the field forward. Here, we discuss biological advances in the core molecular determinants in some of the most common soft-tissue sarcomas – liposarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, Ewing’s sarcoma, and synovial sarcoma – with an emphasis on emerging genomic and molecular pathway targets and immunotherapeutic treatment strategies to combat this confounding disease.

show abstract

Section: Leiomyosarcomamentioning

confidence: 99%

Section: Leiomyosarcomamentioning

confidence: 99%

Section: Leiomyosarcomamentioning

confidence: 99%

Section: Leiomyosarcomamentioning

confidence: 99%

See 2 more Smart Citations

A review of soft-tissue sarcomas: translation of biological advances into treatment measures

Hoang¹,

Acevedo²,

Mann³

et al. 2018

CMAR

109

176

View full text Add to dashboard Cite

show abstract

“…Although it hasn't proved a relationship of this tumor with pregnancy or parity, the higher prevalence in women who received Tamoxifen indicates a correlation with estrogen imbalance [2]. These tumors are considered unpredictable, with a relative resistance to chemotherapy and radiotherapy [3].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis challenges in a uterine leiomyosarcoma

Balan¹,

Andriescu²,

Marin³

et al. 2017

Arch Clin Cases

View full text Add to dashboard Cite

Uterine leiomyosarcoma (LMS) represents a rare tumor, accounting for 1.3% of all uterine malignancies. Although this tumor shares morphological and clinical features with other uterine benign and malignant tumors, the accurate diagnosis is necessary, due to their different biological behavior and prognosis. Therefore, we present a case of LMS in a 48 year-old patient, complaining of a 3-months metrorrhagia. The tumor presented as a poorly defined submucosal nodule, with a soft consistence and measuring 6 cm in diameter. The microscopic examination of this tumor nodule revealed fascicles of spindle cells, with pleomorphic hyperchromatic nuclei exhibiting moderate to severe atypia and areas of tumor necrosis. At least 5 atypical mitoses/ 10 HPF were also found. Immunohistochemistry technique, with a panel of six antibodies, comprising ER, PR, PCNA, SMA, p53, and bcl-2, has been performed for the differential diagnosis. The final histopathological diagnosis was that of uterine LMS. Considering LMS an aggressive tumor, the patient has been recommended a thorough follow-up.

show abstract